Zdrowie i gospodarka · 19/05/1994

FDA Proposes to Disapprove New Drug Application for Deprenyl Gelatin Capsules and Liquid

The US Food and Drug Administration (FDA) proposes to disapprove a new drug application for Deprenyl Gelatin Capsules and Liquid submitted by Discovery Experimental and Development, Inc., citing insufficient information on the safety and efficacy of the treatment for Alzheimer's disease.